Apellis Pharmaceuticals Inc. (APLS) and Biofrontera AG (NASDAQ:BFRA) Contrasting side by side

Since Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and Biofrontera AG (NASDAQ:BFRA) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apellis Pharmaceuticals Inc. N/A 0.00 109.30M -2.05 0.00
Biofrontera AG N/A 0.00 N/A -0.76 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Apellis Pharmaceuticals Inc. 0.00% -62.1% -51.4%
Biofrontera AG 0.00% 0% 0%

Institutional & Insider Ownership

The shares of both Apellis Pharmaceuticals Inc. and Biofrontera AG are owned by institutional investors at 57.6% and 2.17% respectively. Insiders held 20.7% of Apellis Pharmaceuticals Inc. shares. Comparatively, insiders own roughly 0.04% of Biofrontera AG’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Apellis Pharmaceuticals Inc. 17.21% 12.73% 1.64% -12.51% 28.52% -17.14%
Biofrontera AG -2.92% -3.38% -12.98% -11.22% 0% 0.66%

For the past year Apellis Pharmaceuticals Inc. had bearish trend while Biofrontera AG had bullish trend.

Summary

Biofrontera AG beats on 5 of the 6 factors Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.